Proteoform + AI

At Proteoformics, we are at the forefront of a groundbreaking era in oncology therapeutics, with a distinct emphasis on Protein Post-Translational Modifications (PTMs). Our unique approach to target discovery harnesses the intricacies of PTMs, combined with the power of generative AI, to deliver unparalleled specificity in cancer treatments. This dual focus allows us to offer therapies that are not only more effective but also intricately tailored to each patient's unique needs.

The Promise of Human Proteoform

PTMs particularly phosphorylations critically influence protein functions and interactions. However, most treatments target whole proteins, bypassing PTM specifics. This oversight calls for more targeted therapies, especially since 95% of protein phosphorylations remain unexplored. Remarkably, a single protein can have over 300 distinct phosphorylation sites, each with potential therapeutic value. Proteoformics, we are dedicated to bridging this gap, harnessing the potential of these unexplored phosphorylations to drive the next wave of targeted therapies.

100,000+

Phosphorylation sites identified in human

<5%

Phosphosites with a functionally characterized role

<4%

Phosphosites with FDA-approved therapeutics